|
BIOGEN IDEC/ELAN’S ANTEGREN WILL RADICALLY
ALTER THE MULTIPLE SCLEROSIS DRUG MARKET
Antegren to Account for One-Third of the Market in 2013,
According to a New Study from Decision Resources September
13, 2004--Waltham, Mass.--Decision Resources, Inc., one of
the world’s leading research and advisory firms focusing
on pharmaceutical and health care issues, forecasts that Biogen
Idec/Elan’s Antegren will radically alter the multiple
sclerosis drug market. According to the new Pharmacor study
entitled Multiple Sclerosis, Antegren, a monoclonal antibody,
will account for one-third of the market in 2013. The drug
received FDA priority review in July 2004 and is expected
to launch in early 2005.
“Sales of Antegren will be driven by the drug’s
efficacy and more-convenient dosing over currently available
therapies,” said Andrea Witt, Ph.D., analyst at Decision
Resources. “Antegren’s sales will rival that of
all the IFN-ß therapies combined in 2013. Thought leaders
are uniformly excited about the arrival of Antegren, which
they anticipate will be an effective drug with few side effects.”
About Multiple Sclerosis
Multiple sclerosis is a disease of the central nervous system
characterized by the destruction of the myelin sheath surrounding
neurons, resulting in the formation of "plaques."
The disease is a progressive and usually fluctuating condition
with exacerbations (patients feeling worse) and remissions
(patients feeling better) over many decades. Multiple sclerosis
is three times more common in women than in men, and patients
are usually diagnosed as young adults.
About Pharmacor from Decision Resources
Pharmacor is a unique family of studies that assesses a host
of market-impacting factors and analyzes the commercial outlook
for drugs in research and development.
About Decision Resources
Decision Resources, Inc., (www.decisionresources.com)
is a world leader in research publications, advisory services,
and consulting designed to help clients shape strategy, allocate
resources, and master their chosen markets.
###
For more information, contact:
Elizabeth Marshall
Decision Resources, Inc.
781.296.2563
< BACK |
